Skip to main content

Advertisement

SpringerLink
Log in

Assessment of Small Intestinal Transit Times in Ulcerative Colitis and Crohn’s Disease Patients with Different Disease Activity Using Video Capsule Endoscopy

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Small intestinal transit times (SITT) influence drug bioavailability. This study aimed to compare SITT in Crohn’s disease and ulcerative colitis patients with non-inflammatory bowel disease (IBD) and to determine influence of disease activity on transit times, and in addition, to establish the utility of small bowel video capsule endoscopy (SB-VCE) in investigation of SITT in IBD patients. A retrospective review was performed on consecutive patients who had undergone SB-VCE at a university hospital out-patient clinic. In total, 125 non-IBD patients, 55 Crohn’s disease patients, and 23 ulcerative colitis patients were included. SITT were calculated from the first duodenal image to the first cecal image. Disease activity was assessed based on endoscopy results and inflammatory markers (calprotectin, C-reactive protein, erythrocyte sedimentation rate). SITT were longer in ulcerative colitis patients compared to non-IBD patients (median 264 min vs. 216 min, p = 0.010). Patients with active Crohn’s disease (n = 33) also displayed prolonged SITT compared to non-IBD patients (median 253 min vs 216 min, p = 0.017) and patients with quiescent Crohn’s disease (n = 22) (p = 0.005). SITT can be prolonged in IBD patients depending on disease activity which may alter the drug release profiles and clinical response to colonic drug delivery systems. SB-VCE is a simple, non-invasive tool that can be utilized in pharmacokinetic studies to understand drug bioavailability in different patient groups. Moreover, this variability in transit times needs to be simulated in dissolution testing for in vitro in vivo correlations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Davis SS. Formulation strategies for absorption windows. Drug Discov Today. 2005;10(4):249–57.

    Article  CAS  PubMed  Google Scholar 

  2. Yuen KH. The transit of dosage forms through the small intestine. Int J Pharm. 2010;395(1-2):9–16.

    Article  CAS  PubMed  Google Scholar 

  3. Basit AW, Podczeck F, Newton JM, Waddington WA, Ell PJ, Lacey LF. Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine. Pharm Res. 2002;19(9):1368–74.

    Article  CAS  PubMed  Google Scholar 

  4. Koch KM, Parr AF, Tomlinson JJ, Sandefer EP, Digenis GA, Donn KH, et al. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm Res. 1993;10(7):1027–30.

    Article  CAS  PubMed  Google Scholar 

  5. Adkin DA, Davis SS, Sparrow RA, Huckle PD, Wilding IR. The effect of mannitol on the oral bioavailability of cimetidine. J Pharm Sci. 1995;84(12):1405–9.

    Article  CAS  PubMed  Google Scholar 

  6. Fadda HM, McConnell EL, Short MD, Basit AW. Meal-induced acceleration of tablet transit through the human small intestine. Pharm Res. 2009;26(2):356–60.

    Article  CAS  PubMed  Google Scholar 

  7. Fallingborg J, Pedersen P, Jacobsen BA. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn’s disease. Dig Dis Sci. 1998;43(4):702–5.

    Article  CAS  PubMed  Google Scholar 

  8. Sarosiek I, Selover KH, Katz LA, Semler JR, Wilding GE, Lackner JM, et al. The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. Aliment Pharmacol Ther. 2010;31(2):313–22.

    CAS  PubMed  Google Scholar 

  9. Sinha A, Ball D, Connor AL, Nightingale J, Wilding IR. Intestinal performance of two mesalamine formulations in patients with active ulcerative colitis as assessed by gamma scintigraphy. Pract Gastroenterol. 2003;27:56–69.

    Google Scholar 

  10. Safdi AV. Determination of 5-ASA in whole or partial mesalamine delayed release tablets recovered from fecal samples of healthy volunteers. Am J Gastroenterol. 2005;100:S159.

    Google Scholar 

  11. Ibekwe VC, Liu F, Fadda HM, Khela MK, Evans DF, Parsons GE, et al. An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans. J Pharm Sci. 2006;95(12):2760–6.

    Article  CAS  PubMed  Google Scholar 

  12. Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res. 2008;25(8):1828–35.

    Article  CAS  PubMed  Google Scholar 

  13. Varum FJO, Hatton GB, Freire AC, Basit AW. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy. Eur J Pharm Biopharm. 2013;84(3):573–7.

    Article  CAS  PubMed  Google Scholar 

  14. Gotze H, Ptok A. Orocaecal transit time in patients with Crohn disease. Eur J Pediatr. 1993;152(3):193–6.

    Article  CAS  PubMed  Google Scholar 

  15. Castiglione F, Del Vecchio Blanco G, Rispo A, Petrelli G, Amalfi G, Cozzolino A, et al. Orocecal transit time and bacterial overgrowth in patients with Crohn’s disease. J Clin Gastroenterol. 2000;31(1):63–6.

    Article  CAS  PubMed  Google Scholar 

  16. Tursi A, Brandimarte G, Giorgetti G, Nasi G. Assessment of orocaecal transit time in different localization of Crohn’s disease and its possible influence on clinical response to therapy. Eur J Gastroenterol Hepatol. 2003;15(1):69–74.

    Article  PubMed  Google Scholar 

  17. Rao SS, Read NW, Brown C, Bruce C, Holdsworth CD. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology. 1987;93(5):934–40.

    Article  CAS  PubMed  Google Scholar 

  18. Mojaverian P, Vlasses PH, Kellner PE, Rocci Jr ML. Effects of gender, posture, and age on gastric residence time of an indigestible solid: pharmaceutical considerations. Pharm Res. 1988;5(10):639–44.

    Article  CAS  PubMed  Google Scholar 

  19. Neumann H, Fry LC, Nagel A, Neurath MF. Wireless capsule endoscopy of the small intestine: a review with future directions. Curr Opin Gastroenterol. 2014;30(5):463–71.

    Article  PubMed  Google Scholar 

  20. Fischer M, Fadda HM. The effect of sex and age on small intestinal transit times in humans. J Pharm Sci. 2016;105(2):682–86.

  21. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817–26. e2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Jones J, Loftus Jr EV, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6(11):1218–24.

    Article  PubMed  Google Scholar 

  23. Rao SS, Kuo B, McCallum RW, Chey WD, DiBaise JK, Hasler WL, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol. 2009;7(5):537–44.

    Article  PubMed  Google Scholar 

  24. Snape Jr WJ, Matarazzo SA, Cohen S. Abnormal gastrocolonic response in patients with ulcerative colitis. Gut. 1980;21(5):392–6.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Reddy SN, Bazzocchi G, Chan S, Akashi K, Villanueva-Meyer J, Yanni G, et al. Colonic motility and transit in health and ulcerative colitis. Gastroenterology. 1991;101(5):1289–97.

    Article  CAS  PubMed  Google Scholar 

  26. Gilmore IT. Orocaecal transit time in health and disease. Gut. 1990;31(3):250–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chauve A, Devroede G, Bastin E. Intraluminal pressures during perfusion of the human colon in situ. Gastroenterology. 1976;70(3):336–40.

    CAS  PubMed  Google Scholar 

  28. Palma R, Vidon N, Bernier JJ. Maximal capacity for fluid absorption in human bowel. Dig Dis Sci. 1981;26(10):929–34.

    Article  CAS  PubMed  Google Scholar 

  29. Villanacci V, Bassotti G, Nascimbeni R, Antonelli E, Cadei M, Fisogni S, et al. Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil. 2008;20(9):1009–16.

    Article  CAS  PubMed  Google Scholar 

  30. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology. 1996;111(6):1683–99.

    Article  CAS  PubMed  Google Scholar 

  31. Annese V, Bassotti G, Napolitano G, Usai P, Andriulli A, Vantrappen G. Gastrointestinal motility disorders in patients with inactive Crohn’s disease. Scand J Gastroenterol. 1997;32(11):1107–17.

    Article  CAS  PubMed  Google Scholar 

  32. Sarr MG, Kelly KA. Patterns of movement of liquids and solids through canine jejunum. Am J Physiol. 1980;239(6):G497–503.

    CAS  PubMed  Google Scholar 

  33. Szarka LA, Camilleri M. Methods for the assessment of small-bowel and colonic transit. Semin Nucl Med. 2012;42(2):113–23.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Soffer EE. Small bowel motility: ready for prime time? Curr Gastroenterol Rep. 2000;2(5):364–9.

    Article  CAS  PubMed  Google Scholar 

  35. Rao SS, Camilleri M, Hasler WL, Maurer AH, Parkman HP, Saad R, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil. 2011;23(1):8–23.

    Article  CAS  PubMed  Google Scholar 

  36. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–9.

    Article  CAS  PubMed  Google Scholar 

  37. Schreiber S, Hamling J, Zehnter E, Howaldt S, Daerr W, Raedler A, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut. 1997;40(6):761–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Naganuma M, Iwao Y, Ogata H, Inoue N, Funakoshi S, Yamamoto S, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis. 2001;7(3):221–5.

    Article  CAS  PubMed  Google Scholar 

  39. Fadda HM, Merchant HA, Arafat BT, Basit AW. Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems. Int J Pharm. 2009;382(1–2):56–60.

    Article  CAS  PubMed  Google Scholar 

  40. Goyanes A, Hatton GB, Merchant HA, Basit AW. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations. Int J Pharm. 2015;484(1–2):103–8.

    Article  CAS  PubMed  Google Scholar 

  41. U.S. Food and Administration. 2013. Paving the way for personalized medicine: FDA’s role in a new era of medical product development 2013. Available from: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf.

  42. Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012;92(2):203–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Indiana University Division of Gastroenterology and Hepatology, Indianapolis, Indiana, USA

    Monika Fischer, Shivi Siva & John M. Wo

  2. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Butler University, 4600 Sunset Avenue, Indianapolis, Indiana, 46208, USA

    Hala M. Fadda

Authors
  1. Monika Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shivi Siva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John M. Wo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hala M. Fadda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hala M. Fadda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fischer, M., Siva, S., Wo, J.M. et al. Assessment of Small Intestinal Transit Times in Ulcerative Colitis and Crohn’s Disease Patients with Different Disease Activity Using Video Capsule Endoscopy. AAPS PharmSciTech 18, 404–409 (2017). https://doi.org/10.1208/s12249-016-0521-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-016-0521-3

KEY WORDS

Search

Navigation